Free Trial
NASDAQ:GNOM

Global X Genomics & Biotechnology ETF (GNOM) Price, Holdings, & News

$8.64 -0.08 (-0.92%)
Closing price 03:56 PM Eastern
Extended Trading
$8.78 +0.14 (+1.57%)
As of 07:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)

Key Stats

Today's Range
$8.60
$8.86
50-Day Range
$7.43
$9.03
52-Week Range
$6.80
$11.88
Volume
67,620 shs
Average Volume
61,360 shs
Market Capitalization
$43.37 million
Assets Under Management
$43.80 million
Dividend Yield
N/A
Net Expense Ratio
0.50%
Aggregate Rating
Moderate Buy

ETF Overview

Global X Genomics & Biotechnology ETF Expenses

TypeGNOMTheme ETFsEquity ETFsNASDAQ ETFsAll ETFs
Management Fee0.50%0.57%0.56%0.54%0.53%
Other Expenses0.00%0.57%0.56%0.52%0.56%
Total Expense0.50%0.74%0.76%0.73%0.73%
Fee Waiver0.00%-0.76%-0.66%-0.50%-0.63%
Net Expense0.50%0.60%0.63%0.63%0.60%
Receive GNOM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Global X Genomics & Biotechnology ETF and its competitors with MarketBeat's FREE daily newsletter.

GNOM ETF News Headlines

10x Genomics Misses Revenue Forecast
Altucher: Trump’s Great Gain is starting
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.
Global X Genomics & Biotechnology UCITS ETF (GNOM.L)
GNOM Global X Genomics & Biotechnology ETF
See More Headlines

GNOM ETF - Frequently Asked Questions

Global X Genomics & Biotechnology ETF's stock was trading at $9.71 at the beginning of the year. Since then, GNOM stock has decreased by 11.0% and is now trading at $8.64.

Global X Genomics & Biotechnology ETF's top institutional shareholders include Sightline Wealth Advisors LLC (0.99%), Archford Capital Strategies LLC (0.54%), Oxinas Partners Wealth Management LLC (0.32%) and Halbert Hargrove Global Advisors LLC (0.27%).

Shares of GNOM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Global X Genomics & Biotechnology ETF investors own include Meta Platforms (META), NVIDIA (NVDA), Teladoc Health (TDOC), Intel (INTC), Alibaba Group (BABA) and PayPal (PYPL).

Fund Details

Issuer
Global X
Fund Name
Global X Genomics & Biotechnology ETF
Tax Classification
Regulated Investment Company
Stock Exchange
NASDAQ
Current Symbol
NASDAQ:GNOM
Inception Date
4/5/2019
Fund Manager
Chang Kim, James Ong, Nam To, Wayne Xie

Fund Focus

Asset Class
Equity
Benchmark
Solactive Genomics Index
Category
Strategy
Focus
Theme
Development Level
Blended Development
Region
Global
Number of Holdings
51

Fund Statistics

Assets Under Management
$43.80 million
Average Daily Volume
$0.00
Discount/Premium
0.00%

Administrator, Advisor and Custodian

Administrator
Global X Management Company LLC
Advisor
Global X Management Company LLC
Custodian
Brown Brothers Harriman & Co.
Distributor
SEI Investments Distribution Co.
Transfer Agent
Brown Brothers Harriman & Co.
Trustee
N/A
Lead Market Maker
Susquehanna

Options

Optionable
Optionable
Options Volume
1
Put Options
22
Call Options
1
Short Interest
14,000 shs

Miscellaneous

Beta
1.03
Creation Unit
50,000
Creation Fee
$500.00
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for July 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Top 10 GNOM Holdings

GNOM Sector Exposure

GNOM Industry Exposure


This page (NASDAQ:GNOM) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners